GFAP anticorps (N-Term)

N° du produit ABIN357395

Il existe 4+ publications pour ce produit. L’anticorps anti-GFAP Polyclonal Lapin est utilisé pour la détection de GFAP dans des échantillons de Humain. Il a été validé pour WB, IHC (p) et EIA.

Aperçu rapide pour GFAP anticorps (N-Term) (ABIN357395)

Antigène: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp GFAP est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Détail du produit anti-GFAP anticorps

Épitope: N-Term

Specificité: This antibody detects GFAP N-term.

Purification: Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS

Immunogène: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human GFAP.

Isotype: Ig Fraction

Information d'application

Indications d'application: ELISA 1: 1,000. Western blot 1: 100 - 1: 500. Immunohistochemistry 1: 50 - 1: 100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody at 2 - 8 °C up to one month or (in aliquots) at -20 °C for longer.

Références pour anticorps anti-GFAP (ABIN357395)

Curtis, Martin, Gabel, Sidhu, Rzesiewicz, Mandeville, Van Gorp, Leerink, Tadokoro, Marsala, Jamieson, Marsala, Ciacci: "A First-in-Human, Phase I Study of Neural Stem Cell Transplantation for Chronic Spinal Cord Injury." dans: Cell stem cell, Vol. 22, Issue 6, pp. 941-950.e6, (2018) (PubMed).

Kadoya, Lu, Nguyen, Lee-Kubli, Kumamaru, Yao, Knackert, Poplawski, Dulin, Strobl, Takashima, Biane, Conner, Zhang, Tuszynski: "Spinal cord reconstitution with homologous neural grafts enables robust corticospinal regeneration." dans: Nature medicine, Vol. 22, Issue 5, pp. 479-87, (2017) (PubMed).

Lu, Ceto, Wang, Graham, Wu, Kumamaru, Staufenberg, Tuszynski: "Prolonged human neural stem cell maturation supports recovery in injured rodent CNS." dans: The Journal of clinical investigation, Vol. 127, Issue 9, pp. 3287-3299, (2017) (PubMed).

Miyanohara, Kamizato, Juhas, Juhasova, Navarro, Marsala, Lukacova, Hruska-Plochan, Curtis, Gabel, Ciacci, Ahrens, Kaspar, Cleveland, Marsala: "Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs." dans: Molecular therapy. Methods & clinical development, Vol. 3, pp. 16046, (2016) (PubMed).

Détails sur GFAP

Antigène: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Autre désignation: GFAP

Sujet: GFAP is one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system.Synonyms: Glial Fibrillary Acidic Protein

Poids moléculaire: 49880 Da

ID gène: 2670

NCBI Accession: NP_001124491

UniProt: P14136